Novartis reports on Phase II study of AIN 457 in Plaque Psoriasis - 28-Sep-2012

Novartis announced Phase II data showing AIN 457 (secukinumab) may significantly improve moderate-to-severe Plaque Psoriasis on the hands, feet and nails when used every week for the first month of treatment, compared to placebo. Additional analysis on patients with moderate-to-severe Plaque Psoriasis also showed that AIN 457 may successfully improve quality of life by Week 12 in the study. The results will be presented at the European Academy of Dermatology and Venereology (EADV) 21st Congress, in Prague, Czech Republic.

seePaul C, Mroweitz U, Nakayama J et al. Secukinumab, a fully human, anti-interleukin (IL)-17A monoclonal antibody improves signs and symptoms of hand and foot psoriasis: results from a phase II regimen-finding trial. Presented at: 21st Congress of the European Academy of Dermatology and Venereology; 27-30 September, 2012; Prague, Czech Republic. Poster PRA12-0816.